InsiderDB

Lobbying disclosures · Lobbying report

PRAX: third_quarter 2026 lobbying report

Engagement and strategy for the FDA and HHS related to product pipeline.

Follow PRAX
Became public
Aug 17, 2026, 12:21 PM EDT
Event / period date
Not stated
Collected
Nov 9, 2026, 3:19 AM EST

Why this is connected

Exact legal-name match: Praxis Precision Medicines, Inc. (https://www.sec.gov/Archives/edgar/data/1689548/).

Source evidence

Read the source excerpt or record
{"url":"https://lda.gov/api/v1/filings/af66cf23-aacb-4cbb-8471-fd8f85d604c9/","filing_uuid":"af66cf23-aacb-4cbb-8471-fd8f85d604c9","filing_type":"RR","filing_type_display":"Registration","filing_year":2026,"filing_period":"third_quarter","filing_period_display":"3rd Quarter (July 1 - Sep 30)","filing_document_url":"https://lda.gov/filings/public/filing/af66cf23-aacb-4cbb-8471-fd8f85d604c9/print/","filing_document_content_type":"text/html","income":null,"expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Sara Nuvy","dt_posted":"2026-08-17T12:21:43-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"601 Thirteenth St, NW","registrant_address_2":"Suite 250 S","registrant_different_address":null,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20005","registrant":{"id":401104288,"url":"https://lda.gov/api/v1/registrants/401104288/","house_registrant_id":null,"name":"BALLARD PARTNERS","description":"Government relations and advocacy services","address_1":"601 Thirteenth St, NW","address_2":"Suite 250 S","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20005","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"SARA NUVY","contact_telephone":"+1 202-800-5620","dt_updated":"2026-10-22T11:27:44.246261-04:00"},"client":{"id":74612,"url":"https://lda.gov/api/v1/clients/74612/","client_id":74612,"name":"PRAXIS PRECISION MEDICINES, INC.","general_description":"Biopharmaceutical company","client_government_entity":null,"client_self_select":false,"state":"MA","state_display":"Massachusetts","country":"US","country_display":"United States of America","ppb_state":"MA","ppb_state_display":"Massachusetts","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2026-07-11"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Engagement and strategy for the FDA and HHS related to product pipeline.","foreign_entity_issues":null,"lobbyists":[{"lobbyist":{"id":65360,"prefix":null,"prefix_display":null,"first_name":"BRIAN","nickname":null,"middle_name":null,"last_name":"BALLARD","suffix":null,"suffix_display":null},"covered_position":null,"new":true},{"lobbyist":{"id":149096,"prefix":null,"prefix_display":null,"first_name":"SCOTT","nickname":null,"middle_name":null,"last_name":"WAGNER","suffix":null,"suffix_display":null},"covered_position":null,"new":true},{"lobbyist":{"id":153908,"prefix":null,"prefix_display":null,"first_name":"RICHARD","nickname":null,"middle_name":null,"last_name":"HASELWOOD","suffix":null,"suffix_display":null},"covered_position":null,"new":true},{"lobbyist":{"id":148820,"prefix":null,"prefix_display":null,"first_name":"ALISON","nickname":null,"middle_name":null,"last_name":"ANWAY","suffix":null,"suffix_display":null},"covered_position":"LA to Senator Pat Roberts 2006-2010","new":true}],"government_entities":[]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}

Price change after we could observe it

+3.21% PRAX

Adjusted closing prices from Nov 10, 2026 to Nov 11, 2026. SPY changed 1.32% over the same dates. The start is the first available close after both publication and collection. This is a price comparison, not an executed trade, investor profit, or a backtested strategy.

Congressional trading in PRAX

These disclosures provide context. Their presence does not establish a link between a trader and the event.

Original documents control. Public records can be amended, and company connections may require interpretation. Nothing here is investment advice.